DataMeds AI and Tollo Health Announce Fall 2026 Cold & Flu #Back2School50% Marketing Campaign for Viral Infections Medical Food Galectovid(TM)

Rhea-AI Summary

DataMeds AI (NASDAQ: MEDS) announced the U.S. direct-to-consumer launch of medical food Galectovid for the 2026 Cold & Flu season, tied to its #Back2School50% campaign offering 50% off purchases. The product targets galectin‑1 and galectin‑3 associated viral infections and is formulated for dietary management of cellular viral invasion and host immune suppression.

According to DataMeds AI, Galectovid is available over-the-counter without a prescription via partner Tollo Health at www.TolloHealth.Shop and through wholly owned Corexa Pharmacy at www.CorexaRx.com/Store, with future availability planned at Health Lives Here pharmacies and Amazon. Galectovid is classified as a medical food under section 5(b)(3) of the Orphan Drug Act, uses GRAS-listed ingredients, and is intended for use under physician supervision.

Positive

• 50% discount for Fall 2026 #Back2School50% Galectovid DTC campaign
• OTC availability of Galectovid via TolloHealth.Shop and CorexaRx.com/Store
• Defined regulatory category as a medical food with GRAS-listed ingredients

Negative

• None.

News Explained

The release identifies Corexa Health Pharmacy as distributing select Tollo Health products under a wholesale arrangement, clarifying the commercial relationship behind the Galectovid sales channel without disclosing its financial terms.

Market Context

Across five AI-tagged events, the platform recorded an average move of -8.02%, adding historical con...

Analysis

Across five AI-tagged events, the platform recorded an average move of -8.02%, adding historical context to this product launch. The release supplies distribution and regulatory-classification details, but no sales or clinical outcomes; low short positioning remains a separate risk marker.

Key Figures

Campaign discount: 50% off Campaign season: 2026 Galectin targets: Galectin 1 & 3 +1 more

4 metrics

Campaign discount 50% off 2026 Cold & Flu Season #Back2School campaign

Campaign season 2026 Fall Cold & Flu Season

Galectin targets Galectin 1 & 3 Viral infection dietary management

Medical food statute Section 5(b)(3) Orphan Drug Act classification

Previous AI Reports

5 past events · Latest: Aug 14 (Neutral)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Token distribution update	Neutral	+1.4%	Payment date set for previously announced Dream Bowl token distribution
Aug 12	Pharmacy division update	Positive	-5.8%	Corexa Pharmacy reported July revenue above $600,000 and new product availability
Aug 10	Subsidiary renaming	Neutral	-19.6%	Pharmacy subsidiaries renamed under the Corexa Health division
Aug 5	Healthcare initiative feature	Neutral	-11.7%	Television appearance introduced the Health Lives Here initiative
Jul 31	Product distribution launch	Positive	-4.4%	Corexa Pharmacy began direct-to-consumer distribution of Tollo Health products

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Among five AI-tagged events, four were followed by negative 24-hour reactions despite neutral or positive announcements; the average move was -8.02%.

Key Terms

medical food, over-the-counter (OTC), gras, smart contracts

4 terms

medical food medical

"Galectovid is a medical food for the dietary management of Galectin 1 & 3-associated viral infections."

Specialized nutritional products designed to be used under a health professional’s supervision to manage specific medical conditions that have unique dietary needs. Think of them as a tailored meal plan in a bottle or package: not a medicine and not an everyday food, but a regulated product intended to address nutrition gaps tied to a disease. Investors track them because they follow different approval, labeling, and reimbursement rules, which affect market size and sales channels.

over-the-counter (OTC) regulatory

"Galectovid is available over-the-counter (OTC) without a prescription"

Over-the-counter (OTC) describes stocks and other securities traded directly between buyers and sellers outside formal exchanges, using brokers, dealers, or electronic networks. For investors it matters because OTC trading often means lower transparency, fewer rules and thinner trading volume—like buying at a small flea market instead of a big supermarket—so prices can swing more and the risk of not being able to sell quickly is higher.

gras regulatory

"each of its ingredients on the U.S. Food & Drug Administration's Generally Recognized as Safe (GRAS) list."

GRAS stands for “Generally Recognized As Safe,” a U.S. regulatory designation for food ingredients or additives judged safe for their intended use based on scientific evidence or widespread expert consensus. For investors, GRAS status is like a safety stamp or building permit: it reduces regulatory hurdles, shortens time to market and lowers the risk of costly delays or product recalls, which can directly affect a company’s revenue and valuation.

smart contracts technical

"combined with blockchain-enabled smart contracts platform PharmacyChain"

Self-executing digital agreements whose terms are written as code and stored on a distributed ledger so they run automatically when preset conditions are met — like a vending machine that releases a snack only after you insert the right coins. Investors care because smart contracts can speed up transactions, cut middlemen, reduce errors and fraud, and create new ways to issue, trade or enforce financial assets, which affects costs, risk and regulatory oversight.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

This version includes the correct image.

• 50% off available online at www.TolloHealth.Shop and www.CorexaRx.com

• Soon to become available at Health Lives Here™ pharmacies and on Amazon.com

TAMPA, FL / ACCESS Newswire / August 27, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), an integrated healthcare company leveraging its Health IT infrastructure and artificial intelligence platform EinsteinRx™ combined with blockchain-enabled smart contracts platform PharmacyChain™ to provide integrated solutions for the tokenization of pharmaceutical serialization and the compliant delivery of healthcare and monetization of health data, today announced the U.S. 'direct-to consumer' (DTC) launch of medical food Galectovid for the 2026 Cold & Flu Season through its #Back2School50% for 50% off. Galectovid is a medical food for the dietary management of Galectin 1 & 3-associated viral infections targeting cellular viral invasion and host immune suppression.

Galectovid is available over-the-counter (OTC) without a prescription at partner Tollo Health's online store www.TolloHealth.Shop and at the Company's wholly-owned pharmacy Corexa Pharmacy's online store http://www.corexarx.com/Store The effects of Galectovid are expected to begin within hours. Galectovid is categorized as a medical food under section 5(b)(3) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)), with each of its ingredients on the U.S. Food & Drug Administration's Generally Recognized as Safe (GRAS) list. Medical Foods like Galectovid are meant to be taken under the supervision of a physician.

Detailed Galectovid mechanism of action video

"We believe that consumers will be extremely happy with Galectovid as their ally throughout the 2026 Cold & Flu Season," said Gerald Commissiong, interim co-CEO of DataMEDS. "We have begun expanding our Galectovid-focused acute infection research activities through key, pre-established, trusted physician relationships. We look forward to updating physicians and consumers on the potential benefits of Galectovid as new data becomes available."

For more information on DataMeds AI, Inc., refer to www.datamedsai.com

About Galectovid™

Galectovid is a medical food for the dietary management of galectin-1 and galectin-3 associated viral infections. Galectovid is formulated to inhibit galectin-1 and galectin-3 proteins, which are associated with the immune response to and cellular entry of various viruses, including SARS-CoV-2, RSV, Herpes Simplex Virus-1, and Influenza A. Galectovid's ingredients are Generally Recognized As Safe (GRAS) and may be used alongside other natural antiviral products as part of a broader management plan for acute or chronic viral infections, including those associated with Long COVID.

To purchase Galectovid, please visit www.TolloHealth.shop or www.CorexaRx.com/Store.

About Tollo Health, LLC

Tollo Health, LLC is a healthcare company developing and commercializing nature-based therapeutics, including Tollovid and Galcetovid, alongside its Health Lives Here telehealth platform and TolloBio biologics development programs. Corexa Health Pharmacy, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health products under a wholesale distribution arrangement.

About DataMeds AI, Inc.

DataMeds AI, Inc. (formerly Wellgistics Health) is a leading Health IT company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Headquartered in Tampa, Fla., DataMeds AI incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into the Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding: future events, including DataMeds AI, Inc.'s payment of the Dream Bowl Tokens and the timing thereof (including that the Board may change the Payment Date) and the Company's intention to deliver liquidity and broad distribution of the Dream Bowl Tokens. These statements are based on management's current expectations and are not predictions of actual performance.; the Company's plans to expand into telemedicine and diagnostic laboratory services; the Company's proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors; the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the Company's ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the Company's technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com

DataMeds AI Investor Contact
Investor Relations: IR@datamedsai.com

SOURCE: DataMEDS AI, Inc.

View the original press release on ACCESS Newswire

FAQ

What is the DataMeds AI (NASDAQ: MEDS) #Back2School50% Galectovid campaign for Fall 2026?

The #Back2School50% campaign offers Galectovid at a 50% discount for the 2026 Cold & Flu season. According to DataMeds AI, this direct-to-consumer promotion supports broader access to the medical food as students and families prepare for back-to-school viral exposure.

Where can investors and consumers buy Galectovid from DataMeds AI (NASDAQ: MEDS) in 2026?

Galectovid is sold online at www.TolloHealth.Shop and www.CorexaRx.com/Store. According to DataMeds AI, the product is also expected to become available at Health Lives Here pharmacies and on Amazon, expanding its distribution beyond the company’s and Tollo Health’s digital channels.

What type of product is Galectovid in the DataMeds AI (MEDS) portfolio?

Galectovid is categorized as a medical food for managing galectin‑1 and galectin‑3 associated viral infections. According to DataMeds AI, it targets dietary management of cellular viral invasion and host immune suppression, using ingredients that are on the FDA’s Generally Recognized as Safe (GRAS) list.

Does Galectovid from DataMeds AI (NASDAQ: MEDS) require a prescription?

Galectovid is available over-the-counter without a prescription through DataMeds AI’s distribution partners. According to DataMeds AI, it is still intended to be taken under the supervision of a physician because it is regulated as a medical food for specific nutritional management needs.

Which viral infections is Galectovid from DataMeds AI (MEDS) designed to help manage?

Galectovid is formulated for dietary management of galectin‑1 and galectin‑3 associated viral infections. According to DataMeds AI, these include viruses such as SARS‑CoV‑2, RSV, Herpes Simplex Virus‑1, and Influenza A, and may also relate to infections associated with Long COVID.

How quickly does Galectovid from DataMeds AI (NASDAQ: MEDS) begin to work?

The effects of Galectovid are expected to begin within hours of use. According to DataMeds AI, Galectovid is a medical food whose ingredients are Generally Recognized as Safe (GRAS) and should be used under physician supervision as part of an overall viral infection management plan.